The reiteration of a Buy rating and maintenance of a $200 price target by a reputable analyst like Joseph Stringer from Needham is a strong positive signal for Alnylam Pharmaceuticals. This endorsement likely reflects confidence in the company's future performance and growth prospects, which can positively influence investor sentiment and potentially drive the stock price up in the short term.